Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Glaukos Corp (NY: GKOS )

54.85 -0.38 (-0.69%)
Official Closing Price Updated: 7:00 PM EDT, May 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 248,702
Open 55.31
Bid (Size) 52.87 (1)
Ask (Size) 56.58 (1)
Prev. Close 55.23
Today's Range 54.76 - 55.84
52wk Range 39.51 - 61.01
Shares Outstanding 48,208,692
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Glaukos Announces Participation in the William Blair Growth Stock Conference
From Glaukos Corporation
Via Business Wire
Tyson Foods, PayPal And 3 Stocks To Watch Heading Into Monday
With US stock futures trading slightly lower this morning on Monday, some of the stocks that may grab investor focus today are as follows: 
Via Benzinga

Performance

YTD
+25.00%
+25.00%
1 Month
+15.45%
+15.45%
3 Month
+15.45%
+15.45%
6 Month
+18.06%
+18.06%
1 Year
+34.34%
+34.34%

More News

Read More
Glaukos Announces FDA Acceptance of NDA Submission for iDose TR
From Glaukos Corporation
Via Business Wire
Glaukos: Q1 Earnings Insights
Via Benzinga
Glaukos Announces First Quarter 2023 Financial Results
From Glaukos Corporation
Via Business Wire
Expert Ratings for Glaukos
Via Benzinga
Earnings Preview For Glaukos
Via Benzinga
Analyst Expectations for Glaukos's Future
Via Benzinga
Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2023 American Society of Cataract and Refractive Surgery Annual Meeting
From Glaukos Corporation
Via Business Wire
Glaukos Announces the Release of its 2022 Sustainability Report
From Glaukos Corporation
Via Business Wire
Glaukos to Release First Quarter 2023 Financial Results after Market Close on May 3
From Glaukos Corporation
Via Business Wire
10 Analysts Have This to Say About Glaukos
Via Benzinga
What 10 Analyst Ratings Have To Say About Glaukos
Via Benzinga
Glaucoma Is The Second Leading Cause Of Blindness Globally – Skye Bioscience Appears To Be Making Rapid Progress In The Development Of Their Candidate To Treat It
Via Benzinga
Glaukos Submits New Drug Application to U.S. FDA for iDose TR
From Glaukos Corporation
Via Business Wire
NVIDIA To Rally Over 20%? Here Are 10 Other Analyst Forecasts For Thursday
Via Benzinga
Glaukos Announces Fourth Quarter and Full Year 2022 Financial Results
From Glaukos Corporation
Via Business Wire
Glaukos Announces Participation in the Citi Healthcare Conference
From Glaukos Corporation
Via Business Wire
Glaukos to Release Fourth Quarter and Full Year 2022 Financial Results after Market Close on February 22
From Glaukos Corporation
Via Business Wire
Glaukos Announces Positive Results for iDose TR Exchange Trial, Highlighting Favorable Safety and Tolerability
From Glaukos Corporation
Via Business Wire
Glaukos Announces Positive Clinical Updates for Several Corneal Health Pipeline Programs
From Glaukos Corporation
Via Business Wire
Glaukos Announces Participation in the J.P. Morgan Healthcare Conference
From Glaukos Corporation
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For December 22, 2022
Via Benzinga
Skye Bioscience (OTCQB: SKYE) Heads Into 2023 As A Clinical-Stage Company After Dosing Its First Human Participants
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 19, 2022
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.